Vistagen Therapeutics Stock Price, News & Analysis (NASDAQ:VTGN)

$1.19 +0.02 (+1.71 %)
(As of 02/23/2018 11:43 AM ET)
Previous Close$1.19
Today's Range$1.15 - $1.20
52-Week Range$0.69 - $2.75
Volume92,500 shs
Average Volume1.13 million shs
Market Capitalization$26.80 million
P/E Ratio-0.85
Dividend YieldN/A
Beta-1.31

About Vistagen Therapeutics (NASDAQ:VTGN)

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.

Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTGN
CUSIPN/A
Phone650-577-3600

Debt

Debt-to-Equity RatioN/A
Current Ratio10.58%
Quick Ratio10.58%

Price-To-Earnings

Trailing P/E Ratio-0.853478260869565
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.25 million
Price / Sales21.80
Cash FlowN/A
Price / CashN/A
Book Value$0.45 per share
Price / Book2.64

Profitability

Trailing EPS($1.38)
Net Income$-10,250,000.00
Net MarginsN/A
Return on Equity-590.91%
Return on Assets-220.63%

Miscellaneous

Employees9
Outstanding Shares22,900,000

Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

What is Vistagen Therapeutics' stock symbol?

Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

How were Vistagen Therapeutics' earnings last quarter?

Vistagen Therapeutics Inc (NASDAQ:VTGN) announced its earnings results on Monday, February, 12th. The company reported ($0.24) EPS for the quarter. View Vistagen Therapeutics' Earnings History.

Where is Vistagen Therapeutics' stock going? Where will Vistagen Therapeutics' stock price be in 2018?

2 brokerages have issued 12-month target prices for Vistagen Therapeutics' shares. Their predictions range from $4.00 to $22.00. On average, they expect Vistagen Therapeutics' stock price to reach $13.00 in the next year. View Analyst Ratings for Vistagen Therapeutics.

Are investors shorting Vistagen Therapeutics?

Vistagen Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,429,698 shares, an increase of 91.0% from the January 12th total of 748,566 shares. Based on an average daily volume of 1,745,099 shares, the days-to-cover ratio is presently 0.8 days. Currently, 7.1% of the shares of the company are sold short.

Who are some of Vistagen Therapeutics' key competitors?

Who are Vistagen Therapeutics' key executives?

Vistagen Therapeutics' management team includes the folowing people:

  • H. Ralph Snodgrass Ph.D., President, Chief Scientific Officer, Director (Age 67)
  • Shawn K. Singh J.D., Chief Executive Officer, Director (Age 54)
  • Jerrold D. Dotson CPA, Chief Financial Officer, Vice President, Company Secretary (Age 62)
  • Mark A. Smith M.D. Ph.D., Chief Medical Officer (Age 61)
  • Jerry B. Gin Ph.D., Director (Age 74)
  • Jon S. Saxe J.D., Independent Director (Age 80)
  • Brian J. Underdown Ph.D., Independent Director (Age 74)

Who owns Vistagen Therapeutics stock?

Vistagen Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (9.24%), Sphera Funds Management LTD. (5.71%) and Ladenburg Thalmann Financial Services Inc. (0.46%). View Institutional Ownership Trends for Vistagen Therapeutics.

Who bought Vistagen Therapeutics stock? Who is buying Vistagen Therapeutics stock?

Vistagen Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, Sphera Funds Management LTD. and Ladenburg Thalmann Financial Services Inc.. View Insider Buying and Selling for Vistagen Therapeutics.

How do I buy Vistagen Therapeutics stock?

Shares of Vistagen Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vistagen Therapeutics' stock price today?

One share of Vistagen Therapeutics stock can currently be purchased for approximately $1.19.

How big of a company is Vistagen Therapeutics?

Vistagen Therapeutics has a market capitalization of $26.80 million and generates $1.25 million in revenue each year. The company earns $-10,250,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe.

How can I contact Vistagen Therapeutics?

Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]


MarketBeat Community Rating for Vistagen Therapeutics (VTGN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  138
MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vistagen Therapeutics (NASDAQ:VTGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.00$4.00$4.00$4.00
Price Target Upside: 983.33% upside104.08% upside104.08% upside104.08% upside

Vistagen Therapeutics (NASDAQ:VTGN) Consensus Price Target History

Price Target History for Vistagen Therapeutics (NASDAQ:VTGN)

Vistagen Therapeutics (NASDAQ:VTGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018Chardan CapitalLower Price TargetBuy -> Buy$30.00 -> $22.00MediumView Rating Details
4/27/2017Maxim GroupReiterated RatingBuy$4.00MediumView Rating Details
7/7/2016WallachBeth CapitalInitiated CoverageBuy$17.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Vistagen Therapeutics (NASDAQ:VTGN) Earnings History and Estimates Chart

Earnings by Quarter for Vistagen Therapeutics (NASDAQ:VTGN)

Vistagen Therapeutics (NASDAQ VTGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018Q3 2018($0.24)ViewN/AView Earnings Details
11/9/2017Q2 2018($0.48)($0.53)ViewN/AView Earnings Details
8/14/2017Q1 2018($0.28)ViewN/AView Earnings Details
6/29/2017Q4 2017($0.32)ViewN/AView Earnings Details
2/13/2017Q3 2017($0.37)($0.34)$1.25 millionViewN/AView Earnings Details
11/14/2016Q2 2017($0.38)($0.42)ViewN/AView Earnings Details
8/12/2016Q1 2017($0.51)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Vistagen Therapeutics (NASDAQ:VTGN) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.89 EPS

Dividends

Dividend History for Vistagen Therapeutics (NASDAQ:VTGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vistagen Therapeutics (NASDAQ VTGN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Vistagen Therapeutics (NASDAQ VTGN) News Headlines

Source:
DateHeadline
VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial ResultsVistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results
finance.yahoo.com - February 13 at 9:59 AM
Short Interest in Vistagen Therapeutics Inc (VTGN) Rises By 91.0%Short Interest in Vistagen Therapeutics Inc (VTGN) Rises By 91.0%
www.americanbankingnews.com - February 11 at 1:08 AM
Chardan Capital Trims Vistagen Therapeutics (VTGN) Target Price to $22.00Chardan Capital Trims Vistagen Therapeutics (VTGN) Target Price to $22.00
www.americanbankingnews.com - February 8 at 12:56 PM
Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on MondayVistagen Therapeutics (VTGN) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 5 at 4:00 AM
VistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive DisorderVistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive Disorder
finance.yahoo.com - January 30 at 9:31 AM
VistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets Investor ConferenceVistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets' Investor Conference
finance.yahoo.com - January 24 at 8:07 AM
VistaGen Therapeutics (VTGN) Receives FDA Fast Track Designation for AV-101 for the Treatment of MDDVistaGen Therapeutics (VTGN) Receives FDA Fast Track Designation for AV-101 for the Treatment of MDD
www.streetinsider.com - January 4 at 10:22 AM
VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive DisorderVistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder
finance.yahoo.com - January 3 at 9:41 AM
VistaGen Therapeutics to Present at the 10th Annual Biotech ShowcaseVistaGen Therapeutics to Present at the 10th Annual Biotech Showcase
finance.yahoo.com - December 18 at 10:50 AM
VistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common StockVistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
finance.yahoo.com - December 13 at 4:40 PM
Stocks- Wall Street Set for Higher Opening as Bitcoin Futures SurgeStocks- Wall Street Set for Higher Opening as Bitcoin Futures Surge
finance.yahoo.com - December 11 at 11:08 AM
VistaGen Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Patent on Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and CancerVistaGen Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Patent on Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer
finance.yahoo.com - December 8 at 10:27 AM
VistaGen Soars on Patent Announcement, Pipeline Review, and Analysts OpinionVistaGen Soars on Patent Announcement, Pipeline Review, and Analysts Opinion
finance.yahoo.com - December 7 at 10:50 AM
Vistagen Therapeutics Inc (VTGN) Wows Investors with a New Patent VictoryVistagen Therapeutics Inc (VTGN) Wows Investors with a New Patent Victory
finance.yahoo.com - December 6 at 4:31 PM
VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101
finance.yahoo.com - December 6 at 10:42 AM
VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business UpdateVistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - November 12 at 1:17 PM
VistaGen Therapeutics, Inc. (VTGN) Announces Quarterly  Earnings ResultsVistaGen Therapeutics, Inc. (VTGN) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 5:36 PM
VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of DepressionVistaGen Therapeutics Receives European Patent for AV-101 for Treatment of Depression
finance.yahoo.com - November 6 at 9:05 AM
VistaGen Therapeutics, Inc. (VTGN) Scheduled to Post Quarterly Earnings on MondayVistaGen Therapeutics, Inc. (VTGN) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 6:26 AM
Is VistaGen Therapeutics Inc’s (VTGN) Balance Sheet A Threat To Its Future?Is VistaGen Therapeutics Inc’s (VTGN) Balance Sheet A Threat To Its Future?
finance.yahoo.com - November 4 at 6:19 AM
VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive DisorderVistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder
finance.yahoo.com - October 28 at 8:34 AM
Should You Worry About VistaGen Therapeutics Inc (VTGN) Cash Runway?Should You Worry About VistaGen Therapeutics Inc (VTGN) Cash Runway?
finance.yahoo.com - October 6 at 12:41 PM
VistaGen Therapeutics (VTGN) Receives Notice of Allowance for U.S. Patent Regarding Methods of Production for AV-101VistaGen Therapeutics (VTGN) Receives Notice of Allowance for U.S. Patent Regarding Methods of Production for AV-101
www.streetinsider.com - September 30 at 12:50 AM
VistaGen Therapeutics (VTGN) Receives Notice of Allowance for US Patent Regarding Methods of Production for AV-101 - StreetInsider.comVistaGen Therapeutics (VTGN) Receives Notice of Allowance for US Patent Regarding Methods of Production for AV-101 - StreetInsider.com
www.streetinsider.com - September 29 at 2:48 PM
VistaGen Announces Closing of Underwritten Offering of Common Stock and Warrants to Purchase Common StockVistaGen Announces Closing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
finance.yahoo.com - September 7 at 11:06 AM
VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common StockVistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
finance.yahoo.com - September 1 at 11:00 AM
VistaGen Therapeutics Expands VistaStems Scientific Advisory Board with Appointment of Medicinal Chemistry Expert, David Rotella, PhDVistaGen Therapeutics Expands VistaStem's Scientific Advisory Board with Appointment of Medicinal Chemistry Expert, David Rotella, PhD
finance.yahoo.com - August 22 at 7:44 AM
VistaGen Therapeutics, Inc. (VTGN) Releases Quarterly  Earnings ResultsVistaGen Therapeutics, Inc. (VTGN) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 15 at 10:46 AM
VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and CancerVistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer
finance.yahoo.com - August 9 at 8:58 AM
VistaGen Therapeutics Appoints Dr. Mark Wallace to Clinical Advisory Board to Advance AV-101 as a Potential Non-Opioid Treatment for Neuropathic PainVistaGen Therapeutics Appoints Dr. Mark Wallace to Clinical Advisory Board to Advance AV-101 as a Potential Non-Opioid Treatment for Neuropathic Pain
finance.yahoo.com - July 11 at 9:22 AM
VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101
us.rd.yahoo.com - March 29 at 10:09 AM
9:02 am VistaGen: EPO has issued a Notice of Intention to Grant the cos European Patent Application for AV-1019:02 am VistaGen: EPO has issued a Notice of Intention to Grant the co's European Patent Application for AV-101
us.rd.yahoo.com - March 29 at 10:09 AM
Coverage initiated on VistaGen by Maxim GroupCoverage initiated on VistaGen by Maxim Group
us.rd.yahoo.com - March 28 at 10:56 PM
VistaGen Therapeutics Inc. (US: VTGN) to Ring The Nasdaq Stock Market Closing BellVistaGen Therapeutics Inc. (US: VTGN) to Ring The Nasdaq Stock Market Closing Bell
www.marketwatch.com - March 11 at 10:54 AM
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other EventsVISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events
biz.yahoo.com - December 15 at 7:13 AM
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial ConditionVISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - November 14 at 8:33 PM
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersVISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - September 27 at 7:56 PM
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, FinaVISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fina
biz.yahoo.com - August 17 at 8:31 PM
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EVISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
biz.yahoo.com - June 22 at 6:04 AM
VISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial SVISTAGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
biz.yahoo.com - May 16 at 6:29 PM

SEC Filings

Vistagen Therapeutics (NASDAQ:VTGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vistagen Therapeutics (NASDAQ:VTGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vistagen Therapeutics (NASDAQ VTGN) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.